Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients diagnosed with triple-negative breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak piersi z receptorem hormonalnym ujemnym i HER2 ujemnym, mierzalna choroba, przerzutowy lub nieoperacyjny miejscowo zaawansowany
- •Lub nawrotowy, nieoperacyjny surowiczy rak jajnika
- •Wiek od 18 lat
- •Dobry stan sprawności (ECOG ≤2)
- •Zdolność połykania tabletek
- •Prawidłowa funkcja krwi, wątroby, nerek i krzepnięcia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- April 22, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Huntsman Cancer Institute
Salt Lake City, United States
Inova Schar Cancer Institute
Fairfax, United States
Trial contact
Janna Espinosa
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.